Mauna Kea Technologies SAS Cash Flow Conversion Efficiency
Mauna Kea Technologies SAS cash flow conversion efficiency. Based on the latest financial reports, Mauna Kea Technologies SAS (ALMKT) has a cash flow conversion efficiency ratio of 0.077x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.28 Million ≈ $-2.67 Million USD) by net assets (€-29.42 Million ≈ $-34.40 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Mauna Kea Technologies SAS (2010–2024)
Cash flow conversion efficiency of Mauna Kea Technologies SAS from 2010 to 2024. This chart illustrates how Mauna Kea Technologies SAS's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ALMKT stock price and chart for real-time trading data and today's change.
Mauna Kea Technologies SAS Cash Flow Conversion Ratio Explained
Mauna Kea Technologies SAS cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Mauna Kea Technologies SAS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mauna Kea Technologies SAS ranked by their cash flow conversion efficiency. Also see ALMKT stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Naas Technology Inc ADR
NASDAQ:NAAS
|
-0.015x |
|
PLYTEC Holding Berhad
KLSE:0289
|
0.064x |
|
Ikonisys SA
PA:ALIKO
|
-0.014x |
|
Nucletron Electronic Aktiengesellschaft
F:NUC
|
0.004x |
|
EG Corporation
KQ:037370
|
0.034x |
|
Coal Energy S.A.
WAR:CLE
|
-0.005x |
|
Duc Long Gia Lai Group JSC
VN:DLG
|
-0.523x |
|
Cliq Digital AG
XETRA:CLIQ
|
0.120x |
Annual Cash Flow Conversion Efficiency for Mauna Kea Technologies SAS (2010–2024)
The table below shows the annual cash flow conversion efficiency of Mauna Kea Technologies SAS from 2010 to 2024. Review Mauna Kea Technologies SAS (ALMKT) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-24.39 Million ≈ $-28.51 Million |
€-6.32 Million ≈ $-7.39 Million |
0.259x | +494.90% |
| 2023-12-31 | €-17.28 Million ≈ $-20.20 Million |
€-753.00K ≈ $-880.34K |
0.044x | -90.16% |
| 2022-12-31 | €-19.93 Million ≈ $-23.29 Million |
€-8.83 Million ≈ $-10.32 Million |
0.443x | -55.43% |
| 2021-12-31 | €-10.33 Million ≈ $-12.08 Million |
€-10.27 Million ≈ $-12.01 Million |
0.994x | +50.29% |
| 2020-12-31 | €-12.08 Million ≈ $-14.12 Million |
€-7.99 Million ≈ $-9.34 Million |
0.662x | +101.63% |
| 2019-12-31 | €253.00K ≈ $295.78K |
€-10.27 Million ≈ $-12.01 Million |
-40.601x | -2872.05% |
| 2018-12-31 | €7.98 Million ≈ $9.33 Million |
€-10.90 Million ≈ $-12.74 Million |
-1.366x | -134.80% |
| 2017-12-31 | €16.74 Million ≈ $19.58 Million |
€-9.74 Million ≈ $-11.39 Million |
-0.582x | +17.16% |
| 2016-12-31 | €11.16 Million ≈ $13.04 Million |
€-7.84 Million ≈ $-9.16 Million |
-0.702x | +15.62% |
| 2015-12-31 | €14.09 Million ≈ $16.47 Million |
€-11.73 Million ≈ $-13.71 Million |
-0.832x | -18.67% |
| 2014-12-31 | €18.15 Million ≈ $21.22 Million |
€-12.73 Million ≈ $-14.88 Million |
-0.701x | -120.08% |
| 2013-12-31 | €30.16 Million ≈ $35.26 Million |
€-9.61 Million ≈ $-11.24 Million |
-0.319x | +3.61% |
| 2012-12-31 | €40.16 Million ≈ $46.95 Million |
€-13.28 Million ≈ $-15.53 Million |
-0.331x | -176.02% |
| 2011-12-31 | €51.57 Million ≈ $60.30 Million |
€-6.18 Million ≈ $-7.22 Million |
-0.120x | +67.12% |
| 2010-12-31 | €6.86 Million ≈ $8.02 Million |
€-2.50 Million ≈ $-2.92 Million |
-0.364x | -- |
About Mauna Kea Technologies SAS
Mauna Kea Technologies SA manufactures and sells medical devices in Europe and internationally. It offers a range of medical devices for gastroenterology, pulmonology, and urology applications. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform that enables unique in vivo cellular visualization, allowing doctors to monitor disease evolution over time, evaluate… Read more